Monday, 13 July 2021 09:10

Angel group and Scottish Enterprise lead £1.2million cancer trial investment

Michael Leek, Jackie Waring and Angela Scott

Scotland’s only female angel group, Investing Women, and Scottish Enterprise have led a £1.2million investment to fund a cancer therapy trial for patients in Glasgow, Edinburgh, Aberdeen and Southampton.

With support from Scottish Investment Bank and WH Partnership, Investing Women marked their first major investment by raising £680,000 for biotechnology company TC BioPharm’s clinical trial, which will use its ImmuniCell product to treat melanoma, lung and kidney cancer from September.

The equity investment was accompanied by a grant of approximately £500,000 from Scottish Enterprise’s SMART:SCOTLAND programme.

Immunicell is manufactured at a multi-million pound cleanroom at Maxim Office Park near Glasgow. TCB says it has future potential to target major viral infections including severe influenza, HIV and Ebola.

Dr Michael Leek, TCB chief executive, said: “Since commencing operations 16 months ago, TCB has raised over £3.3 million in seed equity and grants. These funds, and the fantastic support from those who contributed, has allowed us to realise our goal – treating cancer patients.”

Jackie Waring, Investing Women’s chief executive, added: “Investing Women is thrilled to lead this investment in TCB which allows the first treatment of cancer patients using ImmuniCell® therapy. It has been an exciting journey, and this is just the start. The team at TCB are at the top of their game, and we have absolute confidence in their ability to deliver amazing results as well as their utter dedication to saving lives.”

  • Facebook Page: 165971433539526
  • Twitter: SBNNAberdeen
  • YouTube: aberdeenbusiness


Scottish Business News Network (SBNN)
111 Gallowgate
Aberdeen
AB25 1BU

T - 01224 619751

E - This email address is being protected from spambots. You need JavaScript enabled to view it.